 | From the Editor's Desk
Moderna's Next Act Is Using mRNA vs. Flu, Zika, HIV, and Cancer The biotech has reached a $100 billion market cap. But after Covid, the challenges get even bigger.
A year ago, Moderna Inc. was an unprofitable company with no marketed products and a promising but totally unproven technology. None of its experimental drugs and vaccines had ever completed a large-scale trial. Experts were divided on how well the mRNA-based Covid-19 vaccine it was about to enter in a Phase III trial would stack up against older, more established vaccine technologies.
This year, Moderna could deliver 1 billion doses of its Covid shot and bring in $19 billion in revenue. It's become the rare biotech to hit the big time without being gobbled up by, or splitting profits with, a larger, more established company. Its market value - which hit $100 billion for the first time on July 14th - exceeds that of stalwarts such as Bayer AG, the German inventor of aspirin, and biotech peers such as Biogen Inc., founded three decades prior.
Continued here
TradeBriefs: Newsletters for Decision-Makers!
Our advertisers help fund the daily operations of TradeBriefs. We request you to accept our promotional emails.
Want the newsletters, without the promotional mailers?
Get an (ad-free) subscription to TradeBriefs Premium for just $2 per month.
|
LifeLife� | � |  | LifeLife | � | | LifeLife
� LifeLife | � | | LifeLifeMonkeypox Case Is Discovered in Texas The rare but potentially serious viral illness was identified in a Dallas resident who had recently returned from Nigeria. Health officials said there was very little risk to the public. | � | | LifeLifeHow Climate Change Hit Wine Country Sunscreen on grapes. Toilet water that is treated and used for irrigation. Napa Valley winemakers are taking extreme steps in the face of climate change. | � | | LifeWork | � | | WorkWork | � | | WorkWork | � | | WorkWorkWorkWorkWorkWorkWhat a tiny bone tells us about Neanderthal thinking It's easy to think we, Homo sapiens, are unique -- that we represent the acme of evolution and will forever sit atop the great chain of being. But it's definitely plausible that we have gotten too self-important. WorkWorkWorkWorkWorkWorkWorkWorkWorkWorkWork TradeBriefs Publications are read by over 10,00,000 Industry Executives |
| View online | Your support of promotional mailers like these (upto 2 per day) helps us keep the TradeBriefs newsletter free for you. Still wish to Unsubscribe? For inquiries/unsubscribe issues, Contact Us |
Postgraduate Diploma in Leadership  | | In collaboration with |  | |  |  | | STARTS ON | | August 20, 2021 | | | | |  | | DURATION | 6 Months Online
2-4 hours per week | | | | | | | | Why Enroll for Postgraduate Diploma in Leadership? | Do you have the leadership skills to take on your next big opportunity and succeed? Strong leaders are needed to guide today's complex organizations into the future, yet 60 percent of C-level executives surveyed in the Global Leadership Forecast 2018 said their failure to attract and retain top leaders was a primary concern.
Emeritus created the Postgraduate Diploma in Leadership program, in collaboration with MIT Sloan, Columbia Business School Executive Education and Tuck School of Business at Dartmouth, to provide a holistic perspective on leadership, with practical frameworks and concepts you can apply immediately in your organization, as well as the chance to explore your leadership future, from where you want to go to the factors and behaviors that could be holding you back—and how to address them. | | | Faculty | | The program is led by experts in leadership and coaching: |  | | Marshall Goldsmith | | Former Faculty at Tuck at Dartmouth |  | | | |  | | Late Katherine Phillips | | Paul Calello Professor of Leadership and Ethics, Senior Vice Dean, Columbia Business School |  | | | |  | | Adam Galinsky | | Vikram S. Pandit Professor of Business Chair of Management Division, Columbia Business School | | | | | |  | | John Van Maanen | | Erwin H. Schell Professor of Management, MIT Sloan School of Management |  | | | | | | Seats are filling quickly for this exciting new offering, and early applications are encouraged. | | | | | 
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
